A spinoff originally from Oregon Health & Science University, in January 2017. TomegaVax was acquired by San Francisco based start-up biotech firm Vir Biotechnology in which ARCH Venture Partners and the Bill & Melinda Gates Foundation are among the lead investors. TomegaVax Inc. is an immunotherapy company organzied around developing cures for AIDS, malaria, tuberculosis, herpes, papillomavirus and hepatitis - â diseases where thereâs no natural immunity in humans and traditional vaccine mechanisms donât work. The approach is to use the CMV virus to trigger a persistent immune response and redirect it to other pathogens.The firm applies a vaccine technology platform to areas of unmet medical need and is focused on the preclinical and clinical development of vaccines and immunotherapies for chronic and recurring viral infections. Tomegavas research team will remain intact and contnue to work in the the OTRADI Bioscience Incu
